CHICAGO, Dec. 19, 2025 — Today, the U.S. Food and Drug Administration approved Boehringer Ingelheim’s nerandomilast (Jascayd) for the treatment of progressive pulmonary fibrosis (PPF) in adults. 

This decision follows the FDA’s Oct. 7, 2025, approval of Jascayd for idiopathic pulmonary fibrosis (IPF). Together, these approvals mark meaningful milestones for people living with pulmonary fibrosis, expanding treatment options and reinforcing progress in care for both IPF and PPF. 

Progressive pulmonary fibrosis is a serious form of interstitial lung disease in which scarring worsens over time, leading to declining lung function and increasing shortness of breath. In the Phase 3 FIBRONEER-ILD clinical trial, nerandomilast slowed the decline in forced vital capacity (FVC), a key measure of lung function, versus placebo over 52 weeks. 

“Progressive pulmonary fibrosis can advance quickly and place significant strain on patients and families,” said Dr. Amy Hajari Case, Chief Medical Officer of the Pulmonary Fibrosis Foundation (PFF). “The FDA approval of nerandomilast for PPF is an important step forward that brings new momentum to care for people living with this disease.”

The PFF remains steadfast in its commitment to advancing research, expanding education, and providing essential support to patients and their families. Together with our partners across the scientific and patient communities, we will continue working toward improved outcomes and, ultimately, a cure for pulmonary fibrosis.

---

 

About the Pulmonary Fibrosis Foundation

The Pulmonary Fibrosis Foundation is committed to accelerating research, empowering our community, and transforming care so that everyone with pulmonary fibrosis can live a better life.  Our ultimate goal is to find a cure for pulmonary fibrosis. The PFF has a four-star rating from Charity Navigator and is an accredited charity by the Better Business Bureau (BBB) Wise Giving Alliance. The Foundation has met all of the requirements of the National Health Council Standards of Excellence Certification Program® and has earned the Guidestar Platinum Seal of Transparency. For more information, visit pulmonaryfibrosis.org or call 844.TalkPFF (844.825.5733)

###